Repligen Corp. announced its plan to acquire BioLife Solutions for about $1.5 billion in an all-cash-and-stock deal that is structured as roughly 64% in Repligen stock and 36% in cash. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen, valuing each BioLife share at about $31 and implying an enterprise value around $1.5 billion. The transaction includes approximately $560 million in cash and 7.2 million Repligen shares, with a total equity value of roughly $1.6 billion and a premium to BioLife’s recent trading levels, subject to closing conditions and regulatory approvals. The deal is expected to close in the fourth quarter, contingent on BioLife stockholder approval and other customary closing conditions, with leadership from both companies signaling alignment on expanding cell-therapy offerings and creating a higher-margin, recurring-revenue business. BioLife’s management emphasizes its market-leading biopreservation portfolio and the strategic fit with Repligen’s biologics manufacturing platform, while Repligen frames the combination as a natural evolution of its growth and leadership in cell-therapy technologies. The communications accompanying the deal include standard forward-looking statements and risk disclosures outlining expected benefits, timing, and potential synergies of the BioLife transaction.